Data from 589 , Bronchiectasis is a chronic respiratory disease of airway dilatation, where patients typically suffer from respiratory infections, fatigue, sputum, cough, dyspnoea and poor quality of life , The Australian Bronchiectasis Registry (ABR), established in 2015, aims to evaluate clinical phenotypes of Australians with bronchiectasis. Uses, Side Effects, & Dosage, What is Formoterol Fumarate? Your doctor may prescribe expectorants and mucus thinners to help you cough up mucus. FOIA What are the critical designations that have been granted for the emerging therapies for Non-cystic Fibrosis Bronchiectasis? ARINA-1 . doi: 10.1002/ccr3.6378. Maintain a healthy diet, low in sodium, added sugars, saturated fats and refined grains. Open AccessPublished:August 05, 2021DOI:https://doi.org/10.1016/j.lanwpc.2021.100239 Aboriginal children have higher rates of , Free training module for paediatric respiratory disease Chronic respiratory disease is prevalent among Aboriginal children but most doctors never had the opportunity to learn about , Bronchiectasis among Australian Aboriginal and non-Aboriginal patients in the regional and remote population of the Northern Territory of Australia Purpose:Chronic respiratory disorders are highly prevalent , Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study This research identifies, for the first time, neutrophil extracellular trap , Improving Aboriginal Childrens Lung Health developed by the Research Education and Training program in Western Australia, is an electronic training module, endorsed by RACGP, , A novel anti-inflammatory treatment for bronchiectasis that targets neutrophils has shown promising results in a phase 2 trial. Neutrophils are the most common type of white blood cell and execute a vital role in pathogen destruction and inflammatory mediation. April 13, 2021 20:20 ET | Source: DelveInsight Business Research LLP As expected, this large number of patients awakened the recognition of an unmet need for effective therapeutic interventions for the management of bronchiectasis. Patients who are compliant with their SmartVest treatment protocols may see a cost savings. 144 Bronchiectasis Clinics. sharing sensitive information, make sure youre on a federal This chronic, progressive respiratory disorder can cause persistent coughing and repeated infections. But there is hope - our Clinical Trials Unit is Read More Our Tax ID is: 131632524. Their first report, published in Respiratory Medicine (Australian , The British Thoracic Society have updated their recommendations and clinical practice points in January 2019. Talk to our experts at the American Lung Association Lung HelpLine and Tobacco QuitLine. The airways normally produce a small amount of mucus (sputum or phlegm) which traps any germs that enter the lungs. MeSH Bronchiectasis is a lung condition that occurs when the bronchial tubes of your lungs are enlarged permanently. INS1007 is an investigational, first-in-class, oral, selective, reversible inhibitor of dipeptidyl peptidase I (DPP1) developed by Insmed to treat Non-cystic Fibrosis Bronchiectasis patients. 13 In a prospective study of 69 children followed for 900 child-months, 36 exacerbations . A new ulcerative colitis research study with Sano Genetics allows you to take part in world-leading research entirely from home. Try to quit smoking if you smoke. Receive premium care & cutting edge treatments by enrolling in bronchiectasis clinical trials today. The trial will last for 52 weeks, and patients who complete the trial will be eligible for an extension where they will receive the drug for at least . Oxygen poses a fire risk, so you should never smoke or use flammable materials when using oxygen. The Bronchiectasis Center at Columbia University Irving Medical Center/NewYork-Presbyterian (CUIMC/NYP) provides exceptional comprehensive care for bronchiectasis patients. Uses, Side Effects, & Dosage, What is Proair Hfa? These patients also have high expenses related to their outpatient treatments [16, 17]. You will now receive email updates from the American Lung Association. This often happens because of a new respiratory infection or overgrowth of bacteria. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. . This review summarized the recent published literatures in order to help clinicians better understand bronchiectasis. In this Review, we discuss the mechanisms and potential roles of emerging therapies, including drugs that target airway and systemic inflammation, mucociliary clearance, and epithelial dysfunction. The bronchiectasis space boasts a modest pipeline of 14 agents for all phases, which is indicative of an overall lack of investment in this therapy area. Your doctor may recommend surgery if the bronchiectasis is isolated to a section of lung, or you have a lot of bleeding. Would you like email updates of new search results? Enhancing veteran mental health with new Associate Director of Mental Health Research, The 2022 Nontuberculous mycobacteria (NTM) Symposium 3-5 Nov. 2018 Nov 15;4(1):45. doi: 10.1038/s41572-018-0042-3. Live Chat with us, Monday through Friday, 8:30 a.m. to 5:00 p.m. EST. Bronchiectasis is a chronic lung disease characterised by inflammation of the airways, mucociliary dysfunction, mucus plugging, and progressive structural damage. Oxygen therapy is a treatment that delivers oxygen for you to breathe. Bronchiectasis is becoming increasingly prevalent, with over 200,000 people estimated to be living with the disease in the UK. This trial is testing a new medication for bronchiectasis called ARINA-1. Although understanding of the pathophysiology of bronchiectasis is at an early stage, we argue that bronchiectasis is a heterogeneous disease with many different biological mechanisms that drive disease progression (endotypes), and therefore the so-called treatable traits approach used in asthma and chronic obstructive pulmonary disease could be applied to bronchiectasis, with future trials targeted at the specific disease subgroups most likely to benefit. . While more research and clinical trials are needed, the top-line results of this study highlight the tremendous value of clinical trials in providing patients with access to more effective, simpler treatments. Unauthorized use of these marks is strictly prohibited. The trial will last for 52 weeks, and patients who complete the trial will be eligible for an extension where they will receive the drug for at least one more year. There are several online and in-person support groups for patients with bronchiectasis. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. A trial of chronic azithromycin treatment in patients with stable non-cystic fibrosis bronchiectasis. Tiotropium via HandiHaler is an established long-acting, anticholinergic bronchodilator that prevents exacerbations and improves lung function in patients with COPD. Right now, there are no approved pharmaceutical therapies out there for patients who are struggling to manage this disease, Principal Investigator and GMRF Respiratory Research Unit Head Associate Professor Rachel Thomson says. Medical management of bronchiectasis: more MDT would help, Respiratory follow up for Aboriginal children, Improving Aboriginal Childrens Lung Health, Bronchiectasis in the Northern Territory, Australia, Neutrophil extracellular traps bronchiectasis, Improving Aboriginal Childrens Lung Health, Brensocatib reduces exacerbations in bronchiectasis: WILLOW study, Epidemiology of bronchiectasis in the UK: Findings from the British lung foundations Respiratory health of the nation projec, Six ways that bronchiectasis treatment is at odds with guidelines. Session 2: Self-management of bronchiectasis. Several studies have shown that many mediators are involved in the pathogenesis of bronchiectasis, such as lipids, platelets, and respiratory microorganisms, providing new . With acquired, or environmental bronchiectasis, damages to the airways can begin during childhood; however, a person might not develop any symptoms until many years later. Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent exacerbations in many patients. Background Neutrophilic inflammation in the airway is a hallmark of bronchiectasis. How many companies are developing therapies for the treatment of Non-cystic Fibrosis Bronchiectasis? Bronchiectasis is an irreversible widening (dilation) of portions of the breathing tubes or airways (bronchi) resulting from damage to the airway wall. We did a systematic review of scientific literature and clinical trial registries to identify agents in early-to-late clinical development for bronchiectasis in adults. In this issue of ERJ Open Research, Phua et al. Often this is due to a new respiratory This trial will test whether two doses of a new drug, brensocatib, can help to prevent pulmonary exacerbations (PEs), which are sudden worsening of symptoms in people with chronic lung disease. This is done with a combination of medication, hydration and chest physical therapy. Eur Respir J. Epub 2019 Jan 16. In 2021, a series of significant research progress have been made in bronchiectasis, focusing on the mechanism, diagnosis, clinical phenotypes, treatment, comorbidities, etc. The goal of bronchiectasis treatment is to prevent infections and flare-ups. Patient: I am a patient with bronchiectasis. New Search; Advanced Search; See Studies by Topic; See Studies on Map . The trial will last 28 days, and participants will be randomly assigned to either take ARINA-1 or a placebo twice daily. Take antibiotics for one to two weeks during flare-ups. Goyal V, Grimwood K, Marchant J, Masters IB, Chang AB. PMC Your tax-deductible donation funds lung disease and lung cancer research, new treatments, lung health education, and more. Bronchiectasis in the Northern Territory, Australia. Frailty and co-morbidities perform a role in determining the appropriateness of these treatments. Non-cystic Fibrosis Bronchiectasis Emerging Drugs. FET involves forcing out a couple of breaths and then doing relaxed breathing. The Bronchiectasis Patient Conference 2022 took place online on Sunday 27 March. Your doctor may recommend surgery if no other treatments have helped and only one part of your airway is affected. Bethesda, MD 20894, Web Policies Chalmers JD, Chang AB, Chotirmall SH, Dhar R, McShane PJ. In these instances, you should contact your doctor immediately. Welsh EJ, Evans DJ, Fowler SJ, Spencer S. Cochrane Database Syst Rev. At the same time, an international expert consensus proposed radiological and clinical diagnosis criteria for inclusion of bronchiectasis patients in clinical trials. European Respiratory Society442 Glossop RoadSheffield S10 2PXUnited KingdomTel: +44 114 2672860Email: journals@ersnet.org, Copyright 2023 by the European Respiratory Society, Diviso de Pneumologia, Instituto do Corao (InCor), Hospital das Clinicas (HCFMUSP), Faculdade de Medicina, Universidade de So Paulo, So Paulo, Brazil. Clipboard, Search History, and several other advanced features are temporarily unavailable. The findings were published in the Internal Medicine Journal, in the study " Metaanalysis of Efficacy and Safety of Inhaled Ciprofloxacin in Noncystic Fibrosis Bronchiectasis Patients." "It is increasingly recognized that patients with COPD have different phenotypes, and treatment can be . Macrolides are a specific type of antibiotics that not only kill certain types of bacteria but also reduce inflammation in the bronchi. . These findings highlight the importance of local data in order to allow this complex scenario of bronchiectasis to be better understood while taking into account all particularities inherent to this pathology. 3 The implications of this guidance for primary care . Uses, Side Effects, & Dosage, What is Advair Hfa? When a patient has a persistent cough with large quantities of phlegm (mucus), the doctor may suspect bronchiectasis and order different types of tests. In 2022 and beyond, the care of patients with asthma will likely be transformed by novel monoclonal antibodies targeting cytokines, new asthma guidelines emphasizing precision medicine, and real-world evidence on the efficacy of newer asthma drugs. Though they may be beneficial for some people, they are only used in the most severe situations because they have extreme side-effects. Make sure your loved one seeks treatment for his/her bronchiectasis, especially during a severe exacerbation. A fairly uncommon disease, there are about 139 cases per 100,000 adults in the United States, and it tends to affect women more often than it does men. A new cutting-edge treatment for patients with chronic obstructive pulmonary disease (COPD) has been carried out by experts at Royal Brompton and Chelsea and Westminster hospitals in London as part of a research trial. Trikafta is the first approved treatment that is effective for cystic fibrosis patients 12 years and older with at least one F508del mutation, which affects 90% of the population with cystic . This is the 3rd cardiac med that has been prescribed in hopes of . The British Thoracic Society (BTS) guideline for non-cystic fibrosis bronchiectasis, covering adults and children, was published in 2010 and updated in 2013. By helping patients better manage repeated infections and inflammation, you can greatly reduce the suffering associated with this disease, enabling people to get on with their lives.. 2015 Jul 14;2015(7):CD010337. Chinese Medical Association Publishing House Ltd. doi: 10.3760/cma.j.cn112147-20220111-00036. They found high age-standardised incidence of hospitalised bronchiectasis that declined from 13.9 per 100000 persons in 2007 to 10.6 per 100000 persons in 2017 (an average decline of 2.7% per year). This trial is testing a new medication to see if it helps people with bronchiectasis. The https:// ensures that you are connecting to the Sievert, CE et al. Because bronchiectasis remains an underdeveloped area of respiratory careunlike COPD or cystic fibrosismost patients are unfamiliar with its causes, symptoms, and effective treatment methods. Bronchiectasis is more common in women than in men. Internationally, bronchiectasis is increasingly common with prevalence rates currently around 5 per 1000 in the UK population.1 Data from primary care have confirmed comorbid disease in two-thirds of patients, with asthma and chronic obstructive pulmonary disease (COPD) being the most common comorbidities in 42% and 36%, respectively.1 The Bronchiectasis Severity Index . All viewers of this content, especially those taking prescription or over-the-counter medications, should consult their physicians before beginning any nutrition, supplement or lifestyle program. We did a systematic review of scientific literature and clinical trial registries to identify agents in early-to-late clinical development for bronchiectasis in adults. sharing sensitive information, make sure youre on a federal Federal government websites often end in .gov or .mil. You will now receive email updates from the American Lung Association. Chassagnon G, Brun AL, Bennani S, Chergui N, Freche G, Revel MP. The incidence rate of bronchiectasis increased sharply with age for both men and women, as previously described [4]. Patients who have lived with COPD with many years often develop bronchiectasis. Am I at more risk of getting COVID-19 than somebody , A recent paper in Respiratory Medicine has shown that the prevalence and incidence of bronchiectasis in the UK is increasing, with a 3% increase in , Results from the Australian Bronchiectasis Registry (ABR) show a gap between guideline recommendations and real-world treatment of bronchiectasis, even in tertiary centres. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Symptoms are chronic cough and purulent sputum expectoration; some patients may also have fever and dyspnea. Sign up to receive email notifications on clinical trials for individual conditions in your local area. We hypothesized that tiotropium would reduce pulmonary exacerbations and improve lung function in patients with stable bronchiectasis and airflow limitation, and assessed the effect of tiotropium on these outcomes. Scenario: COVID-19: Covers management when considering the possibility of COVID-19. The site is secure. How many patents are granted and pending for the emerging therapies to treat NCFBE. This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. All players (patients, healthcare professionals and payers) will benefit from this. April 13, 2021 20:20 ET
It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. In 2021, a series of significant research progress have been made in bronchiectasis, focusing on the mechanism, diagnosis, clinical phenotypes, treatment, comorbidities, etc. We present an approach to the multi-biome that integrates bacterial, viral . Mucus Thinning Medication may be prescribed to help bronchiectasis patients cough up mucus. Introduction. Some of these devices are Oscillating Positive Expiratory Pressure (PEP), Intrapulmonary Percussive Ventilation (IPV) and Postural Drainage. These medicines are given through an IV line inserted into your arm. ACB is FET that involves deep breathing exercises. Despite the existence of variability in the rate of hospitalisation related to bronchiectasis between countries, the impact of this condition on health systems is unquestionable. Bronchiectasis is a complex and heterogeneous condition characterised by persistent airway dilation, mucus hypersecretion, and recurrent respiratory infectious exacerbations. However, several other costs must be taken into account when assessing patients with bronchiectasis. Your doctor may help you arrange for a home care provider to give you IV antibiotics at home. Bronchiectasis affects 350,000 to 500,000 people in the United States. It focused on treatment and self-management. Some patients may be eligible for Clinical Trials. eCollection 2023 Jan. Liu Y, Du L, Zhu Y, Liu X, Zhou N, Li C, Li Q, He P. Acta Biochim Biophys Sin (Shanghai). These infections are associated with greater lung function decline, increased number of exacerbations and reduced life expectancy [13]. New and Current Treatments for COPD Medically reviewed by Adithya Cattamanchi, M.D. DelveInsight Business Research LLP, Los Angeles, USA, April 13, 2021 (GLOBE NEWSWIRE) -- Non-cystic Fibrosis Bronchiectasis Treatment 2021 | Prominent Players, Pipeline Growth, Future Trends, Unmet Demands, Emerging Therapies: DelveInsight. 2021 First Bronchiectasis Trial. 2.2 Bronchiectasis Treatment Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028 2.3 Global Bronchiectasis Treatment Market Size by Region (2017-2022) You can also call the Lung Association's Lung Helpline at 1-800-LUNGUSA to talk to a trained respiratory professional who can help answer your questions and connect you with support. COPD is an umbrella term for a collection of conditions causing lung damage, including chronic bronchitis and emphysema, and affects around three million people in the UK. Individual results may vary. Due to the recurrent use of several courses of oral antibiotics and severity of some patients, many episodes of exacerbations require hospital admission for intravenous antibiotic therapy, with a minimum recommended duration of 1014days [810]. FOIA Bronchiectasis often is treated with medicines, hydration, and chest physical therapy (CPT). Study Summary. At one point I also used nebulized tobramycin. Learn more about bronchiectasis symptoms, causes, diagnosis, and treatment. Take your place in a new project exploring the genetics of Parkinsons. A .gov website belongs to an official government organization in the United States.
Expert Opin Pharmacother. Early diagnosis and treatment of the underlying cause of bronchiectasis may help prevent further lung damage. No treatments have been licensed by regulatory agencies worldwide, and most therapies used in clinical practice are based on very little evidence. Which are the dormant and discontinued products and the reasons for the same? Milder cases that did not require hospitalisation during the evaluated period were not considered. 2018 Feb 7;2(2):CD012528. For further information, refer to the detailed report @ NCFBE Pipeline Therapeutics, Scope of Non-cystic Fibrosis Bronchiectasis Pipeline Drug Insight, Key Questions regarding Current Non-cystic Fibrosis Bronchiectasis Treatment Landscape and Emerging Therapies Answered in the Pipeline Report, Get a customised pipeline report @ Non-cystic Fibrosis Bronchiectasis Drugs Pipeline Report. 2016 May;51(5):450-69. doi: 10.1002/ppul.23380. 2022 Sep;82(14):1453-1468. doi: 10.1007/s40265-022-01785-1. The risk of developing bronchiectasis increases with age. Vascular Grafts Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Vascular Grafts market. The treatment of bronchiectasis will be reviewed here. 77 References. Antibioticsare the most common treatment for bronchiectasis. HHS Vulnerability Disclosure, Help Reviewed and approved by the American Lung Association Scientific and Medical Editorial Review Panel. Clinical Trial Guide for Seniors and the Elderly, Clinical Trial Guide for Parents and Children, Guide To Keeping Your Health Records Secure, Clinical Trials on the Effects of Bullying, Clinical Trials on the Positive Effects of Gardening and Experiencing Nature, Clinical Trials on the Disaster Mental Health, A Guide to Bronchiectasis and Clinical Trials, https://www.bmj.com/rapid-response/2011/11/01/role-pneumococcal-and-influenza-vaccination-management-bronchiectasis, https://www.nhlbi.nih.gov/health-topics/bronchiectasis, https://www.lung.org/lung-health-and-diseases/lung-disease-lookup/bronchiectasis/diagnosing-and-treating.html. The study, Vitamin D , Lung Foundation Australia have recently updated their bronchiectasis action plan. Unauthorized use of these marks is strictly prohibited. This trial will study the effects of Trikafta on non-cystic fibrosis bronchiectasis sufferers, measuring clinical endpoints, quality of life and weight, plus collecting biopsy material to test cellular response. Bronchiectasis what are the stages and symptoms. A rare coincidence of Turner syndrome and bronchiectasis: A case report. In chronic inflammatory lung diseases, neutrophils garner in the airways and result in major active NSPs that cause lung destruction and inflammation. best treatment plan for you. It is undeniable that our scientific knowledge related to bronchiectasis has significantly evolved. PMC Bronchiectasis is a long-term condition with symptoms that need to be managed over many years. Print 2018 Sep. Respirology. Promising progress in new treatment for bronchiectasis sufferers, For people with bronchiectasis, the symptoms and exacerbations of the disease can have a debilitating impact on their quality of life. Smoking affects your lungs and can cause further damage. We only share your information with the clinical trials you're trying to access. We do not capture any email address. 2 The British Thoracic Society guideline for bronchiectasis in adults was published in 2019. The clinical phenotype of bronchiectasis and its clinical guiding implications. announced from one of our clinical trials into a new treatment for bronchiectasis. eCollection 2022 Sep. Bronchiectasis: an update on current pharmacotherapy and future perspectives. Thank you for your interest in spreading the word on European Respiratory Society . MeSH Read the study Diagnosis. National Library of Medicine There are number of ways you can get involved and support innovative medical research. Non-cystic Fibrosis Bronchiectasis Therapies Late-stage (Phase III), Non-cystic Fibrosis Bronchiectasis Therapies Early-stage (Phase I), NCFBE Pre-clinical stage and Discovery candidates. Expectorants help loosen the mucus in your lungs. Federal government websites often end in .gov or .mil. Healthy volunteers needed for important new studies (compensation available). When facing a disease as heterogeneous as bronchiectasis is, we should expect different results according to countries and regions. Until a few decades ago, bronchiectasis was considered an orphan disease due to its low prevalence, little recognition of its importance even by pulmonologists, and lack of proven effective therapies for its management. You can sit with your head tilted down or lie on your stomach with your head down while you do CPT. New therapeutic options for Non-cystic Fibrosis Bronchiectasis treatment as 5+ companies are working for the drug profiles. The authors found that the annual direct medical cost associated with bronchiectasis was USD 9.6 million in 2017. A new website, called Strong Lungs, has been launched that is specifically designed for Aboriginal and Torres Strait Islander adults with bronchiectasis. Uses, Side Effects, & Dosage, What is Incruse Ellipta? The U.S. Food and Drug Administration (FDA) has permitted breakthrough therapy designation for. DPP1 is an enzyme held to activate neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when formed in the bone marrow. Sign up today for your free Reader Account! New frontiers in the treatment of COPD. While most patients with bronchiectasis have chronic symptoms, a particularly severe episode is called an exacerbation. DelveInsight's Non-Cystic Fibrosis Bronchiectasis (NCFB) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of NCFB. But there is hope our Clinical Trials Unit is at the forefront of innovative new treatments. Some of the key takeaways of the Non-cystic Fibrosis Bronchiectasis Pipeline Report, Get an overview of pipeline landscape @ Non-cystic Fibrosis Bronchiectasis Clinical Trial Analysis. 1 A GP practice of 10,000 patients will have around 50 adult patients with bronchiectasis. We believe in providing patients with all the options. Uses, Side Effects, & Dosage, What is Tobi Podhaler? In addition, researches on bronchiectasis comorbidities also have new findings. This site needs JavaScript to work properly. The U.S. Food and Drug Administration (FDA) has given fast track designation to RedHill Biopharma 's RHB-204 as a potential first-line and stand-alone, oral treatment for lung infections caused by Mycobacterium avium complex (MAC), a type of non-tuberculous mycobacteria (NTM). In recent years, we have experienced an exponential increase in studies focused on unravelling the pathophysiology of bronchiectasis, on testing different therapeutic interventions and on evaluating its socioeconomic burden. Treatment with the inhaled antibiotic ciprofloxacin can reduce the frequency of exacerbations, or sudden disease flare-ups, in people with bronchiectasis, a new analysis indicates.. Bronchiectasis. Please enable it to take advantage of the complete set of features! Good hydration helps keep airway mucus moist and slippery and easier to cough up. The condition makes the airways permanently broadened and inflamed. Chest congestion can be a symptom of an underlying health condition that may be acute or chronic. Your doctor may prescribe other medicines, depending on your symptoms or other conditions you may have. Secure .gov websites use HTTPS In Germany, the direct expenditure with bronchiectasis was 31.0% higher than matched controls (mean EUR 18634.57 versus EUR 14236.99) [16]. Our service is free and we are here to help you. Some suggestions may be: Despite maintaining a healthy lifestyle, occasional flare-ups may occur. Jun 3, 2021 4:59 PM. What are the current options for Non-cystic Fibrosis Bronchiectasis treatment? This trial will test a new device that monitors heart rate, breathing rate, temperature, cough, and activity to see if it can predict worsening or increasing severity of lung conditions. Official websites use .gov nhoward. The document summarised the epidemiology, pathogenesis, etiology, clinical diagnosis, treatment strategies and patient education of bronchiectasis in China according to a systematic review of the . National Library of Medicine The growing body of patients attending the bronchiectasis clinic has also permitted extensive research into new and improved treatments for bronchiectasis. Symptoms such as increased mucus (sputum) production that is bloody or a different color, fever, fatigue, weight loss and worsening shortness of breath may be a sign youre experiencing a flare-up.